CytoDyn Appoints Dr. Richard Pestell as Lead Oncology Consultant
CytoDyn, a biotech company working on leronlimab, a CCR5 antagonist with the potential for diverse therapeutic applications, has appointed Dr. Richard Pestell, M.D., Ph.D., as the Lead Consultant in Preclinical and Clinical Oncology. With over three decades of research experience, Dr. Pestell will lead CytoDyn’s efforts in oncology, drawing on his expertise to advance the clinical evaluation of leronlimab for cancer treatment.
Based in Pennsylvania, Dr. Pestell currently heads the Pennsylvania Cancer and Regenerative Medicine Research Center. He previously led research at Thomas Jefferson University in Philadelphia, where he served as Director of the Sidney Kimmel Cancer Center. Dr. Pestell’s work spans over 600 publications, cited more than 95,000 times. His contributions were instrumental in obtaining Fast Track Designation from the FDA for leronlimab in treating CCR5-positive metastatic triple-negative breast cancer.
Dr. Jacob Lalezari, CEO of CytoDyn, expressed excitement about Dr. Pestell joining the team, emphasizing his potential to advance oncology clinical trials. Dr. Pestell shared in this enthusiasm, noting leronlimab’s promise in enhancing patient care and treatment options in oncology. Dr. Pestell holds degrees from the University of Western Australia and the University of Melbourne, among other accolades for his substantial contributions to the field of oncology.
CytoDyn’s focus on developing leronlimab for various applications, including oncology and inflammation, represents a step forward in innovative treatments. It’s essential to bear in mind that this information is based on current expectations of future events and may be subject to updates as new developments unfold.
